Cutting Edge Research in Hepatocellular Carcinoma

Guest Editor

Dr. Cheng-Maw Ho
Department of Surgery, National Taiwan University Hospital, Taipei, Taiwan
miningho@ntu.edu.tw

Message from the Guest Editor

Dear Colleagues,

Hepatocellular carcinoma (HCC) is one of the most common malignancies worldwide. Multiple lines of research ranging from epidemiology, carcinogenesis, diagnostics, and therapeutics (including surgery and liver transplantation) had been actively in progress, to reduce the disease burden and to achieve primary, secondary, and tertiary prevention of HCC. Recent advances in immunotherapy further improve the prognosis of advanced HCC. This special issue welcomes articles in all areas related to HCC, either clinical, translational, or basic research in nature. Topics of cell therapy with sound scientific evidence or personalized medicine are especially welcome. Because liver reserve is a key factor limiting the therapeutic option of HCC, studies related to this (for example, liver fibrosis, cirrhosis, liver failure, and regeneration) are also considered. Other areas can include viral or metabolic liver diseases which predispose to liver cirrhosis and HCC development. Articles that present cell line studies should be accompanied with in vivo validation. Review articles can be extensive or focused analyses. Policy papers or papers related to education (either healthcare education or public education) can be accepted after review. I hope to receive your excellent work included in this special issue and contribute to literature in the field of HCC significantly.

Sincerely,
Dr. Cheng-Maw Ho
Guest Editor
Submission Deadline: 30 April 2022

Submission: https://www.fbscience.com/Landmark

Science Citation Index Expanded: 4.009 (2020)

Contact us: Front.Biosci.Landmark@fbscience.com